Interim

Isofol Medical AB (publ) publishes interim report, January–June 2024

By

GOTHENBURG, Sweden, August 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Second quarter, April–June 2024 Net revenue amounted to kSEK 0 (0) and […]

Isofol Medical AB (publ) publishes interim report, January–June 2024 Read More »

Isofol Medical AB (publ) publishes interim report, January–March 2024

By

GOTHENBURG, Sweden, May 8, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. First quarter, January–March 2024 Net revenue amounted to kSEK 0 (721) and

Isofol Medical AB (publ) publishes interim report, January–March 2024 Read More »

Isofol Medical AB (publ) publishes year-end report, January – December 2023

By

GOTHENBURG, Sweden, February 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report for January – December 2023 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Fourth quarter, October – December 2023 Net revenue amounted to kSEK 0

Isofol Medical AB (publ) publishes year-end report, January – December 2023 Read More »

Isofol Medical AB (publ) publishes interim report, January–September 2023

By

GOTHENBURG, Sweden, November 10, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2023 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Third quarter, July – September 2023 Net revenue amounted to TSEK 0

Isofol Medical AB (publ) publishes interim report, January–September 2023 Read More »

Isofol Medical AB (publ) publishes interim report, January–June 2023

By

GOTHENBURG, Sweden, August 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2023 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Second quarter, April–June 2023 Net revenue amounted to TSEK 0 (4,027) and other revenue

Isofol Medical AB (publ) publishes interim report, January–June 2023 Read More »

Isofol Medical AB (publ) publishes interim report, January–March 2023

By

GOTHENBURG, Sweden, May 3, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2023 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. First quarter, January–March 2023 Net revenue amounted to TSEK 721 (4,006) and

Isofol Medical AB (publ) publishes interim report, January–March 2023 Read More »

Isofol Medical AB (publ) publishes year-end report, January – December 2022

By

GOTHENBURG, Sweden, February 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report for January – December 2022 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Fourth quarter, October – December 2022 Net revenue amounted to TSEK 1,857

Isofol Medical AB (publ) publishes year-end report, January – December 2022 Read More »

Isofol Medical AB (publ) publishes interim report, January–September 2022

By

GOTHENBURG, Sweden, November 11, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2022 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Third quarter, July – September 2022 Net revenue amounted to TSEK 2,907 (5,154) and

Isofol Medical AB (publ) publishes interim report, January–September 2022 Read More »

Isofol Medical AB (publ) publishes interim report, January–June 2022

By

GOTHENBURG, Sweden, August 23, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2022 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Second quarter, April–June 2022 Net revenue amounted to TSEK 4,027 (7,333) and other revenue

Isofol Medical AB (publ) publishes interim report, January–June 2022 Read More »

Isofol Medical AB (publ) publishes interim report, January–March 2022

By

GOTHENBURG, Sweden, May 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2022 is now available on the company’s website, www.isofolmedical.com (https://isofolmedical.com/investors/financial-reports/). First quarter, January–March 2022 Net revenue amounted to TSEK 4,006 (5,215) and other revenue to TSEK 1 (0) The result for the period amounted

Isofol Medical AB (publ) publishes interim report, January–March 2022 Read More »

Scroll to Top